Source link : https://www.newshealth.biz/health-news/t-dm1-boosts-survival-in-her2-positive-breast-cancer/
TOPLINE: Trastuzumab emtansine (T-DM1) demonstrates sustained improvement in invasive disease-free survival and reduced the risk for death in human epidermal growth factor receptor 2 (HER2)-positive breast cancer compared with trastuzumab. At 7 years, invasive disease-free survival and overall survival was 80.8% and 89.1%, respectively, with T-DM1 compared with 67.1% and 84.4%, respectively, with trastuzumab,. METHODOLOGY: […]
Author : News Health
Publish date : 2025-01-16 12:50:35
Copyright for syndicated content belongs to the linked Source.